Join us on the 2nd February for our first in person 'In Conversation' event with Farah Huzair and Jack Scannell in #Edinburgh on ways to improve the decline in drug R&D productivity. eventbrite.co.uk/e/why-is-drug-…

Looking for insights on R&D productivity and drug discovery? Look no further! Join us for a special podcast recording with Dr. Jack Scannell, CEO of Etheros Pharmaceuticals. Dr. Scannell will shed light on the complex world of pharmaceutical innov…lnkd.in/dkNGFUbJ

Check out our next in-person event: Why is drug R&D so much less efficient now than it was in 1950?" eventbrite.co.uk/e/why-is-drug-… Cafe Synthetique Edinburgh Chemistry Edinburgh SULSA Edinburgh Cancer Research Edinburgh Infectious Diseases Midlothian Science @SynthSysEd Royal Society of Edinburgh @crm_edinburgh ScotSci Edinburgh SCI Scotland Group OU in Scotland

Save the date! The 14th Annual GoldLab Symposium will be held on Thursday, May 18 and Friday, May 19, 2023. Guests will have the option to attend virtually or in-person. Stay tuned for more details!

Tired of being depressed by my R&D podcasts? Well, this Thursday, you can be depressed in person:

In 2020, I recorded a seminar on the typical errors that people make when analysing the economics of the drug industry. I would like to thank the BMJ and the LSE for making the seminar relevant again: youtube.com/watch?v=3LGqQJ…

Discussing the Future of IP-NFTs with the Molecule Tech & Product team and VitaDAO 💛. 📍 Zuzalu, Montenegro

$50 billion a year is spent on failed cancer drug development by the pharma industry. Our new paper is a case study on what goes wrong. Consilium Scientific John A Hickman jamanetwork.com/journals/jaman…

Why do some people say it costs a gazillion dollars to discover a new drug while others say it costs the same as Big Mac? check out supplement 1 of our cancer drug paper for a primer on methods to estimate drug R&D costs. @jhickmana Consilium Scientific

The high, and redundant, cost of failure in cancer drug development bit.ly/3Ou1JMc Drug developers spent US$1.6–2.3 billion to test 16 inhibitors of IGF1R in 183 cancer trials in more than 12,000 patients — without a single oncology approval to show for it

Good new drugs are rare, so bad disease models are false positive machines. Nature Reviews Drug Discovery Consilium Scientific John A Hickman

My prediction for tomorrow’s Mail on Sunday: “Woke bacteria hate Britain”

Don't read? Well, here is the podcast: labiotech.eu/podcast/beyond…

1/ In our latest blog we chat to one of our advisors, Dr Jack Scannell, about the issues in biopharma R&D. Jack is known for coining the term ‘Eroom’s Law’ in his 2012 paper, “Diagnosing the Decline in Pharmaceutical R&D Efficiency,” published in Nature Reviews Drug Discovery.

How does therapeutic progress relate to disease models' "predictive validity"? Very strongly. Good models identify good drugs which eventually render the models redundant. Lousy models continue in use for decades because medical need remains "unmet". nature.com/articles/s4157…

Screening and disease models in drug R&D generally identify drug candidates then fail to work in people. So Ochre Bio had a cunning plan; use real human livers to model real human livers. Jack O'Meara

Thanks to Lea Degen for having me back on the DeSci podcast....

At first glance, the R&D cost measure in this new paper in Nature Reviews Drug Discovery is calculated in a way that does not reconcile with the costs in company accounts, which are maybe >= 2x higher. If so, the paper's "R&D productivity ratios" are a flattering.

Estimating drug industry R&D costs per new drug is a methodological quagmire. Numbers don't mean much unless you know how they are calculated. See here: ncbi.nlm.nih.gov/pmc/articles/P…